Mira Pharmaceuticals Files 8-K: $1.5M Stock Sale & Nasdaq Bid Price Notice
Ticker: MIRA · Form: 8-K · Filed: Aug 23, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Aug 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: financing, compliance, delisting-risk
TL;DR
Mira Pharma raising $1.5M via stock sale, but Nasdaq says bid price too low.
AI Summary
Mira Pharmaceuticals, Inc. announced on August 23, 2024, that it entered into a securities purchase agreement on August 20, 2024, to issue and sell approximately $1.5 million of its common stock and warrants. The company also disclosed that it received a notice from Nasdaq on August 16, 2024, regarding its non-compliance with minimum bid price requirements.
Why It Matters
The company is raising capital through a stock sale, which could dilute existing shareholders, while also facing potential delisting from Nasdaq due to low stock price.
Risk Assessment
Risk Level: medium — The company is raising capital which can be dilutive, and it is also facing a Nasdaq bid price deficiency, indicating potential delisting.
Key Numbers
- $1.5M — Capital Raised (Amount to be raised through sale of common stock and warrants.)
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- August 23, 2024 (date) — Report Date
- August 20, 2024 (date) — Securities Purchase Agreement Date
- $1.5 million (dollar_amount) — Amount of common stock and warrants to be sold
- August 16, 2024 (date) — Nasdaq Notice Date
- Nasdaq (company) — Exchange where stock is listed
FAQ
What is the total amount of common stock and warrants Mira Pharmaceuticals plans to issue and sell?
Mira Pharmaceuticals plans to issue and sell approximately $1.5 million of its common stock and warrants.
When was the securities purchase agreement entered into?
The securities purchase agreement was entered into on August 20, 2024.
What was the reason for the notice from Nasdaq?
Nasdaq issued a notice regarding Mira Pharmaceuticals' non-compliance with minimum bid price requirements.
On what date did Mira Pharmaceuticals receive the notice from Nasdaq?
Mira Pharmaceuticals received the notice from Nasdaq on August 16, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.
Filing Stats: 738 words · 3 min read · ~2 pages · Grade level 13.8 · Accepted 2024-08-23 16:15:12
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 44KB
- 0001493152-24-033718.txt ( ) — 216KB
- mira-20240823.xsd (EX-101.SCH) — 3KB
- mira-20240823_lab.xml (EX-101.LAB) — 33KB
- mira-20240823_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACEUTICALS, INC. Dated: August 23, 2024 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer